Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Splicing01:32

RNA Splicing

56.3K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.3K
Alternative RNA Splicing02:18

Alternative RNA Splicing

21.1K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Testosterone replacement therapy increases 2 and 5 year reoperation rates after posterior lumbar fusion: a propensity-matched analysis of 1808 surgical patients.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2026
Same author

Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute Leukemias.

Cancer discovery·2026
Same author

Circadian chronotype distribution among young adults in Yemen.

Chronobiology international·2026
Same author

CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis.

Nature genetics·2026
Same author

Pubic bone osteomyelitis outcomes in patients with malignancies: a case series from an academic cancer center.

Journal of bone and joint infection·2026
Same author

Disorders of the coccyx and sacrococcygeal joint: Etiology, diagnosis, and management strategies.

The American journal of medicine·2025

Related Experiment Video

Updated: Jun 27, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.9K

GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies.

Salima Benbarche1, Jose Mario Bello Pineda2, Laura Baquero Galvis3

  • 1Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Molecular Cell
|April 30, 2024
PubMed
Summary

Mutations in SF3B1 cause cancer by altering RNA splicing. Researchers identified GPATCH8 as a key factor in this mis-splicing, and silencing it improved cancer models, offering a potential therapeutic strategy.

Keywords:
DHX15G-patch domainGPATCH8RNASF3B1SUGP1leukemiamyelodysplastic syndromessplicing

More Related Videos

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K
Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.0K

Related Experiment Videos

Last Updated: Jun 27, 2025

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.9K
Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors
08:57

Author Spotlight: Genetically Engineered Mouse Models and Pathological Characterization of Neurofibromatosis Type 1 Associated Tumors

Published on: May 17, 2024

1.9K
Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.0K

Area of Science:

  • Molecular Biology
  • Cancer Genetics
  • RNA Splicing Mechanisms

Background:

  • Mutations in the SF3B1 gene are prevalent in various cancers, leading to widespread RNA mis-splicing.
  • Current therapies cannot effectively correct SF3B1-mutant-induced splicing defects.

Purpose of the Study:

  • To identify trans-acting factors involved in aberrant splicing driven by mutant SF3B1.
  • To explore the therapeutic potential of targeting these factors in SF3B1-mutant cancers.

Main Methods:

  • Utilized synthetic introns responsive to mutant SF3B1 to screen for interacting trans-factors.
  • Employed gene silencing techniques to assess the role of identified factors.
  • Evaluated effects on hematopoiesis in mouse models and human progenitors.

Main Results:

  • Identified GPATCH8 as a crucial factor for mutant SF3B1-mediated splicing alterations and impaired hematopoiesis.
  • GPATCH8 interacts with DHX15 and opposes SUGP1, influencing branchpoint selection.
  • Silencing GPATCH8 corrected a significant portion of SF3B1-dependent splicing defects and improved hematopoiesis.

Conclusions:

  • GPATCH8 is a novel splicing factor essential for SF3B1-mutant-associated mis-splicing.
  • Targeting GPATCH8 demonstrates therapeutic promise for correcting aberrant splicing in SF3B1-mutant cancers.